AUM Biosciences is a global clinical-stage biotech company, focused on discovering, developing and advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company’s lead program, AUM has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotecl models, and has contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM001, is a best-in-class MNK inhibitor targeting MSS Colorectal Cancer and many other tumor types by selective inhibition of oncogenic protein translation. The company has a portfolio of assets with clear de-risking mechanisms put in place.